Form 4: Humacyte Director Keith Anthony Jones Granted 80,000 Stock Options

Humacyte, Inc. has reported that Director Keith Anthony Jones was granted 80,000 stock options with an exercise price of $2.41 per share, vesting over four years.

Summary

• Keith Anthony Jones, a Director of Humacyte, Inc. (HUMA), was granted 80,000 stock options.
• The options have an exercise price of $2.41 per share.
• The grant date for these options was June 12, 2025.
• The options will vest over a period of four years, with the first 25% becoming exercisable on June 12, 2026.
• Following the initial vesting, 1/48th of the total option grant will become exercisable on the 12th of each month through June 12, 2029.
• The expiration date for these stock options is June 12, 2035.
• Following this transaction, Keith Anthony Jones beneficially owns 80,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports a standard compensation event (stock option grant) for a director, which is generally a neutral to slightly positive signal as it aligns management interests with shareholders. There are no negative implications or significant new financial data to alter this.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance and value creation.
• The vesting schedule encourages continued commitment and retention of the director.

Future Outlook

The document outlines a future vesting schedule for the granted stock options, with the first tranche becoming exercisable on June 12, 2026, and subsequent monthly vesting through June 12, 2029. The options have an expiration date of June 12, 2035.

Management Comments

• The filing was signed by Dale A. Sander as Attorney-in-Fact for Keith Anthony Jones, indicating the transaction was formally reported on behalf of the director.

Industry Context

This Form 4 filing represents a routine insider transaction, specifically the grant of equity compensation to a director. Such grants are a common practice across various industries, including biotechnology and healthcare (where Humacyte operates), to incentivize executive and board member performance and align their financial interests with long-term company success.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, including those in the biotechnology sector.
• The vesting schedule, which includes an initial cliff vesting followed by monthly vesting over several years, is a common structure designed to encourage long-term commitment and retention, comparable to compensation practices at companies like Gilead Sciences or Amgen for their non-employee directors.

Related Party Transactions

• The grant of 80,000 stock options to Keith Anthony Jones, a Director of Humacyte, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options could lead to future dilution if exercised, but also aims to align the director's interests with shareholder value creation.
• Director (Keith Anthony Jones): Directly benefits from the potential future value of the options, contingent on company performance and stock price appreciation.

Next Steps

• The stock options will begin to vest on June 12, 2026, with subsequent monthly vesting through June 12, 2029.
• The director may choose to exercise the vested options at any time before their expiration on June 12, 2035.

Key Dates

Keywords

Humacyte, HUMA, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Vesting Schedule